Central Nervous System Therapeutics Market Size and Forecast to 2035

Introduction:

The Global Central Nervous System (CNS) Therapeutics Market is witnessing significant growth, driven by the rising prevalence of neurological and psychiatric disorders, increasing awareness regarding mental health, and growing investments in innovative drug development. CNS therapeutics are widely used for the treatment of conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, depression, anxiety disorders, and schizophrenia. Advancements in neuroscience research, expanding healthcare infrastructure, and increasing adoption of targeted and personalized treatment approaches are expected to support long-term market growth globally.

Get Free Sample Of This Premium Report:

https://www.decisionsadvisors.com/request-sample/DAR4104

Central Nervous System Therapeutics Market Insights

Based on Deep Market Insights findings, the Global Central Nervous System Therapeutics Market was valued at USD 125.45 Billion in 2024 and is projected to reach USD 295.84 Billion by 2035.

From 2025 to 2035, the market is expected to grow at a CAGR of 8.11%.

Within the Drug Class category, Antidepressants dominated in 2024 in terms of market size contribution.

Over the forecast period, Biologics, Gene Therapies, and Advanced Neurodegenerative Disease Treatments are forecasted to deliver the fastest growth due to increasing research activities, expanding therapeutic applications, and rising demand for effective treatment options for complex neurological disorders.

Other Key Findings

• North America accounted for a significant share of the global Central Nervous System Therapeutics Market in 2024 and remained a major revenue-generating region.
• North America is expected to emerge as the fastest-growing regional market during the forecast period owing to increasing healthcare expenditure, strong pharmaceutical research capabilities, and rapid adoption of innovative CNS therapies.
• Europe remained a key regional market supported by advanced healthcare systems and growing awareness of neurological and mental health disorders.
• Rising prevalence of neurodegenerative diseases, expanding clinical research activities, and increasing approvals of novel therapeutics continue to support global market growth.

Report Summary

Report Scope

Segmentation Covered

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Drivers, Industry Trends, Technology Advancements, Regulatory Landscape, Clinical Research Analysis, Drug Development Assessment, and Regional Analysis.

Companies

Pfizer Inc., Novartis AG, Johnson & Johnson, Eli Lilly and Company, AbbVie Inc., Bristol Myers Squibb, Biogen Inc., Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., and F. Hoffmann-La Roche Ltd.

Want detailed insights, forecasts, and competitive analysis?

Check out the full report now:
https://www.decisionsadvisors.com/reports/central-nervous-system-therapeutics-market